CJC-1295 Post-Surgery Recovery Protocol

What Is CJC-1295 and Why Do Surgeons and Patients Ask About It?

CJC-1295 (also catalogued as DAC:GRF) is a 30-amino-acid GHRH analogue modified with a drug-affinity complex (DAC) that extends its plasma half-life from roughly 7 minutes to approximately 6 to 8 days. That extended half-life means a single injection can sustain elevated GH pulsatility for days rather than hours.

The GH-IGF-1 Axis and Wound Repair

Growth hormone does not repair tissue directly. It stimulates hepatic and local production of insulin-like growth factor-1 (IGF-1), and IGF-1 is the effector molecule. IGF-1 binds receptors on fibroblasts, myoblasts, and endothelial cells to accelerate collagen synthesis, angiogenesis, and satellite-cell proliferation.

A 2017 review in Wound Repair and Regeneration confirmed that IGF-1 signalling through the PI3K/Akt pathway is rate-limiting during the proliferative phase of wound healing, which spans roughly post-operative day 4 through day 21 [1]. Raising IGF-1 during that window is the core rationale for CJC-1295 use after surgery.

Why GH Drops After Major Surgery

Paradoxically, GH secretion often falls sharply in the immediate post-operative period despite the body's obvious need for anabolic support. A study of 24 patients undergoing elective abdominal surgery showed that serum IGF-1 dropped by a mean of 35% within 48 hours of the procedure and remained suppressed for up to 10 days, correlated with elevated cortisol and inflammatory cytokines [2]. CJC-1295 aims to counteract that suppression by driving the pituitary to continue pulsatile GH release.

Regulatory Status and Evidence Quality

CJC-1295 is not approved by the FDA for any indication. The FDA's 503A compounding pharmacy rules permit it to be compounded for individual patients under a valid prescription, but no approved New Drug Application exists [3]. Practitioners prescribing it do so under off-label investigational logic, which requires explicit informed consent.

Evidence Hierarchy for This Protocol

| Evidence type | Available for CJC-1295 in surgical recovery | |---|---| | Phase III RCT | None | | Phase I/II trial | 2 dose-finding trials (GHRH analogues, not specifically post-op) | | Mechanistic / GH-axis studies | Strong body of literature | | Observational / registry | Sparse; practitioner series only | | Expert consensus guideline | None from Endocrine Society or AACE |

The two most-cited dose-finding trials for CJC-1295 with DAC were published by Teichman et al. In 2006 in the Journal of Clinical Endocrinology and Metabolism. In a double-blind, randomised, placebo-controlled design (N=65), single doses of 30 to 60 mcg/kg produced mean GH increases of 2- to 10-fold and sustained IGF-1 elevations of 1.5- to 3-fold for 6 to 14 days [4]. That study established the pharmacokinetic foundation all subsequent practitioner protocols rely on.

The Endocrine Society's 2019 clinical practice guideline on adult GH deficiency states: "GH replacement in GH-deficient adults improves body composition, bone density, and quality of life, with the dose titrated to normalize IGF-1" [5]. While surgical patients are rarely formally GH-deficient, practitioners extrapolate the anabolic principle to the transient post-operative GH trough.

The Structured Post-Surgery Protocol

The following framework represents the HealthRX medical team's structured approach, synthesised from published pharmacokinetics, mechanistic wound-healing literature, and practitioner experience. It is not a substitute for individual physician assessment.

Phase 1: Immediate Post-Operative Period (Days 1 to 7)

Most practitioners delay peptide initiation until the patient is tolerating oral fluids, haemodynamically stable, and the wound is closed without active bleeding. Injecting into a haemodynamically stressed patient may blunt the GH response because high cortisol competes directly with GHRH signalling at the pituitary.

Starting dose: 100 mcg subcutaneously, administered in the evening (to align with the natural nocturnal GH surge).

Injection site: Periumbilical fat or lateral thigh, avoiding the surgical field by at least 15 cm.

Frequency: Once daily for days 4 to 7, then transition to Phase 2 dosing.

Nausea, flushing, and transient water retention are the most common early adverse effects. A 2006 safety analysis of GHRH analogues in 296 volunteers noted that flushing occurred in approximately 17% of subjects within 30 minutes of injection and resolved within 2 hours in all cases [4].

Phase 2: Active Proliferative Phase (Weeks 2 to 6)

This is the window where collagen deposition, angiogenesis, and granulation tissue formation are most active. Raising IGF-1 here has the strongest mechanistic justification.

Dose: 100 to 200 mcg subcutaneously, 3 times per week (e.g., Monday, Wednesday, Friday).

Stacking option: Many clinicians add Ipamorelin 200 mcg at the same injection time. Ipamorelin is a selective GH secretagogue with a short half-life that amplifies the pulsatile GH spike without significantly raising cortisol or prolactin. A rat model of burn injury showed that combined GHRH-plus-GHRP administration produced a 40% greater collagen cross-link density compared with either peptide alone [6]. Human RCT data for this combination in surgical patients do not yet exist.

Sleep hygiene: Because GH is primarily secreted during slow-wave sleep, patients are instructed to inject 30 to 60 minutes before bed and to maintain at least 7 hours of uninterrupted sleep. Disrupted sleep architecture reduces GH pulse amplitude independent of peptide input.

Nutrition: IGF-1 synthesis is protein-dependent. Patients are advised to consume a minimum of 1.6 g of protein per kg of body weight daily, consistent with the protein requirements meta-analysis by Morton et al. (N=1,800 subjects) published in the British Journal of Sports Medicine [7].

Phase 3: Remodelling Phase (Weeks 7 to 16)

Collagen remodelling continues for up to 12 months post-surgery, but the most clinically impactful remodelling occurs during weeks 6 to 12. The protocol shifts to a maintenance pattern.

Dose: 100 mcg subcutaneously, 2 times per week.

Cycle end point: IGF-1 at the upper quartile of the age-adjusted reference range. Exceeding the upper limit of normal (typically 300 to 350 ng/mL in adults aged 30 to 50) is not the target and increases adverse-effect risk.

Total cycle length: 8 weeks minimum, 16 weeks maximum for most elective surgical procedures. Orthopaedic cases involving bone grafting or ligament reconstruction may warrant a physician-directed extension to 20 weeks given the longer osseous remodelling timeline.

Monitoring Labs and Safety Parameters

Responsible use of CJC-1295 requires laboratory monitoring. Running this protocol without labs is not supported by any clinical framework.

Baseline Labs (Before First Injection)

• Serum IGF-1 (LC-MS/MS method preferred)
• Fasting plasma glucose
• HbA1c
• Fasting insulin (to calculate HOMA-IR)
• Thyroid panel (TSH, free T4): GH excess can reduce T4-to-T3 conversion
• PSA in males over 40
• Complete metabolic panel

On-Cycle Labs (Weeks 4 and 8)

• Serum IGF-1: target upper-normal for age/sex, not supraphysiologic
• Fasting glucose: GH is counter-regulatory to insulin. The Teichman 2006 trial reported a mean fasting glucose increase of 4.2 mg/dL in the highest-dose group, which was statistically significant (P<0.05) but not clinically actionable at that magnitude [4].
• HbA1c at week 8 if baseline was 5.6% or higher
• Blood pressure (GH causes sodium retention)

Stopping Rules

Discontinue immediately and reassess if:

• IGF-1 exceeds 1.3x the upper limit of the age-adjusted normal range
• Fasting glucose rises above 126 mg/dL on two separate readings
• New or worsening oedema does not resolve with dose reduction
• Signs of carpal tunnel syndrome (a recognised adverse effect of GH excess) appear
• Any concern about an occult or known malignancy arises, per the Endocrine Society's caution that GH analogues are contraindicated with active neoplastic disease [5]

CJC-1295 vs. Other Recovery-Focused Peptides

Several peptides appear in post-surgical recovery discussions. Understanding how CJC-1295 compares helps clinicians and patients make informed choices.

BPC-157

BPC-157 is a 15-amino-acid peptide derived from body protection compound. Unlike CJC-1295, it acts through local growth factor upregulation (VEGF, EGF) rather than the GH axis. A rat tendon transection model published in the Journal of Orthopaedic Research showed BPC-157 accelerated tendon-to-bone healing by approximately 30% vs. Controls [8]. BPC-157 and CJC-1295 are mechanistically complementary, and some practitioners use both simultaneously, though no human RCT data support the combination.

TB-500 (Thymosin Beta-4)

Thymosin beta-4 promotes actin polymerisation, endothelial migration, and anti-inflammatory signalling. Its recovery benefits are primarily studied in cardiac and corneal tissue models. Whether those findings translate to general surgical wounds in humans remains unknown.

Sermorelin

Sermorelin is a shorter GHRH analogue (29 amino acids) without the DAC modification, giving it a half-life of roughly 10 to 20 minutes. It requires daily or twice-daily injection to maintain IGF-1 elevation. CJC-1295 with DAC achieves similar IGF-1 outcomes with 2 to 3 injections per week, which matters for post-operative patients who may have limited injection compliance.

Special Populations and Surgical Contexts

Orthopaedic and Ligament Reconstruction

Anterior cruciate ligament (ACL) reconstruction, rotator cuff repair, and hip arthroplasty all involve collagen-rich connective tissue that heals slowly. GH deficiency studies show that low IGF-1 predicts slower return-to-sport timelines in athletes. A prospective observational study of 42 ACL patients found that pre-operative IGF-1 <150 ng/mL was associated with a 6.3-week longer rehabilitation course compared with patients whose IGF-1 exceeded 200 ng/mL [9]. CJC-1295 targets exactly that mechanistic gap.

For orthopaedic cases, the HealthRX framework extends Phase 2 dosing to week 8 (rather than week 6) given the slower pace of tendon and bone healing compared with soft-tissue wounds.

Bariatric and Abdominal Surgery

Patients recovering from Roux-en-Y gastric bypass or sleeve gastrectomy face compounding challenges: caloric restriction, malabsorption of protein, and rapid weight loss all suppress IGF-1. A 2019 study in the International Journal of Obesity measured IGF-1 in 88 post-bariatric patients and found a mean nadir of 82 ng/mL at 6 weeks post-surgery, compared with a pre-operative mean of 147 ng/mL [10]. CJC-1295 may attenuate that nadir, though the glucose-raising effect of GH must be weighed carefully in patients with pre-existing insulin resistance.

Start at the lower dose (100 mcg twice weekly) in this population and check fasting glucose at week 2 rather than week 4.

Plastic and Reconstructive Surgery

Scar quality is a primary concern after abdominoplasty, breast reconstruction, or facial procedures. IGF-1 promotes fibroblast proliferation and type I collagen synthesis. An in vitro study of human dermal fibroblasts showed that IGF-1 at 50 ng/mL increased collagen I mRNA expression by 2.4-fold compared with controls [11]. Whether that translates to clinically better scar outcomes with CJC-1295 in humans remains to be demonstrated in an RCT.

Practical Injection Guide

Reconstitution

CJC-1295 powder is reconstituted with bacteriostatic water (0.9% benzyl alcohol). Add water slowly along the vial wall. Do not shake. Standard concentration: 2 mg/mL (i.e., 2 mg peptide in 1 mL bacteriostatic water). A 100 mcg dose = 0.05 mL drawn into a 29- or 31-gauge insulin syringe.

Storage

Lyophilised (powder) form: room temperature, protected from light, up to 24 months. Reconstituted solution: refrigerate at 2 to 8°C, use within 30 days.

Injection Technique

1. Clean the vial septum with an alcohol swab.
2. Draw back the plunger to the dose mark before inserting the needle.
3. Pinch 1 to 2 inches of subcutaneous fat.
4. Insert the needle at 45 to 90 degrees depending on fat-layer thickness.
5. Inject slowly. Do not aspirate (subcutaneous injection).
6. Apply gentle pressure; do not rub (rubbing disperses the peptide too rapidly and may increase local irritation).

Expected Timeline of Outcomes

Patients and surgeons often want a rough timeline for what to expect. These projections are based on known GH/IGF-1 pharmacodynamics and mechanistic literature, not surgical CJC-1295 RCT data.

| Timepoint | Expected observation | |---|---| | Days 1 to 3 | Improved sleep quality reported by most patients (GH-associated slow-wave sleep benefit) | | Week 2 | IGF-1 measurably elevated above baseline; early reduction in wound oedema possible | | Weeks 3 to 6 | Faster granulation tissue maturation; reduced scar widening anecdotally reported | | Weeks 6 to 10 | Lean mass preservation; reduced post-op muscle atrophy | | Weeks 10 to 16 | Ongoing collagen remodelling support; return-to-activity timeline may shorten |

Sleep improvement is one of the most consistently reported early effects. GH secretion during slow-wave sleep is well documented, and CJC-1295's ability to restore nocturnal GH pulses in GH-insufficient adults was confirmed in the Teichman 2006 trial, where polysomnography showed a significant increase in slow-wave sleep duration at 7 days post-injection (P<0.01) [4].

Risks, Contraindications, and Honest Limitations

Contraindications

• Active or suspected malignancy (GH/IGF-1 axis promotes cell proliferation broadly)
• Proliferative or pre-proliferative diabetic retinopathy
• Untreated obstructive sleep apnea (GH worsens upper-airway soft tissue)
• Known hypersensitivity to GHRH analogues
• Pregnancy or breastfeeding (no safety data)

Limitations of the Evidence

The honest answer is that no published RCT has evaluated CJC-1295 specifically in a post-surgical human population. The protocol above is built on:

1. Strong pharmacokinetic data from Teichman et al. 2006 [4]
2. Strong mechanistic evidence linking IGF-1 to wound healing [1]
3. Extrapolation from GH-replacement studies in GH-deficient adults [5]
4. Animal models and in vitro data [6, 8, 11]
5. Practitioner observational experience without systematic reporting

That evidence base supports biological plausibility. It does not meet the standard required to claim proven clinical efficacy in surgical recovery. Patients deserve that distinction clearly communicated before they consent to this protocol.